2008 PBL Cat_mech_r.qxd:PBL Catalog.mech 11/29/07 1:50 PM Page 3
New Product Highlights
Mouse Interferon Alpha Subtypes Available for the first time, mouse interferon alpha subtypes allow more
detailed investigation of innate immunity in the mouse model system. Please see pages 14–15 for product information.
Comparison of Mouse Alpha-A and Mouse Comparison of Mouse Alpha-A and Mouse
Alpha-4 Antiviral Activity Alpha-11 Antiviral Activity
100 100
75 75
i
o
n
i
o
n
e
ct
50
e
ct
50
P
r
ot
P
r
ot
% %
25 25
0 0
012345 -1 01234
[IFN] log (pg/ml) [IFN] log (pg/ml)
iLite
TM
Human Interferon Alpha Cell-Based
Assay Kit
IFN Dose Response Curve:
Alpha Subtype Specificity
A simple and rapid cell-based assay for detection and
quantification of Type I interferon bioactivity
12,00
• Compatibility with serum, plasma, and culture supernatants
U)
10,00
allows for maximum assay flexibility
(RL
• Unique gene reporter-based bioassay eliminates infectious
t
s
8,00
virus preparations and continuous cell culture requirements t
U
ni
6,00
• Rapid set up and data generation reduces experiment time
gh
Li
to as little as 7 hours instead of days
e 4,00
iv
• Quantitative and sensitive units measurement increases
R
e
l
a
t
2,00
data reproducibility
• Low inter- and intra-assay variability ensures data
0,00
0,10 1,00 10,00 100,00 1000,00 10000,00 100000,00
confidence
• Results correlate well with CPE antiviral assay [IFN] (pg/ml)
• See page 29 for more information
License Your Product to PBL!PBL has worked with scientists around the world and offers generous product
licensing terms. Have you developed any novel IFN reagents that you feel would be of interest to the research community?
If so, please write us at info@interferonsource.com
www.interferonsource.com Tel: +1 732-777-9123
I
Fax: +1 732-777-9141
3
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62